US20130245089A1 - Method for administration - Google Patents
Method for administration Download PDFInfo
- Publication number
- US20130245089A1 US20130245089A1 US13/759,647 US201313759647A US2013245089A1 US 20130245089 A1 US20130245089 A1 US 20130245089A1 US 201313759647 A US201313759647 A US 201313759647A US 2013245089 A1 US2013245089 A1 US 2013245089A1
- Authority
- US
- United States
- Prior art keywords
- day
- compound
- days
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- TVTXCJFHQKSQQM-LJQIRTBHSA-N COC1=CC(C(=O)O)=CC=C1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(C2=CC=C(Cl)C=C2F)[C@H]1C1=C(F)C(Cl)=CC=C1 Chemical compound COC1=CC(C(=O)O)=CC=C1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(C2=CC=C(Cl)C=C2F)[C@H]1C1=C(F)C(Cl)=CC=C1 TVTXCJFHQKSQQM-LJQIRTBHSA-N 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.
Description
- This application claims the benefit of U.S. Provisional Application No. 61/612,429, filed Mar. 19, 2012, which is hereby incorporated by reference in its entirety.
- The present invention is related to improved methods of administration of 4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid (referred to herein as Compound A) in the treatment of cancer. In particular, the invention relates to improved methods of administration of Compound A that provide desirable antineoplastic effects with a tolerable level of toxicity. The methods of the invention are characterized by administering less frequent doses comprising relatively high concentrations of Compound A. This protocol is expected to be safer and at least as effective as, possibly more effective than, administering more frequent doses at lower concentrations or larger doses at intermittent periods.
- Compound A is an orally administered pyrrolidine that inhibits the binding of MDM2 to p53 and is thus useful in the treatment of cancer. It has the following chemical structure:
- Compound A recently entered into phase I clinical trials for the treatment of solid tumors. See ClinicalTrials.gov, identifier NCT01462175. This compound is disclosed in US Pub 2010/0152190 A1. To the extent necessary, this patent publication is herein incorporated by reference.
- Applicants have discovered that Compound A is especially effective, and best tolerated, in cancer therapy when administered in the specific doses and pursuant to the specific protocols herein described.
- The present invention relates to a method of treating a patient suffering with cancer, in particular colon, breast, prostate, lung or kidney cancer or osteosarcoma, comprising administering to the patient Compound A in an amount of from about 800 to about 3000 mg/day, or from about 1000 to about 2500 mg/day, or from about 1250 to about 1800 mg/day, for an administration period of up to about 7 days, preferably up to about 5 days, on days 1-7, or preferably days 1-5, of a 28 day treatment cycle, followed by a rest period of from about 21 to about 23 days, preferably up to about 23 days.
-
FIG. 1 illustrates the antitumor activity, as demonstrated by the change in mean tumor volume over time, of Compound A monotherapy for a number of different dosing schedules, including a continuous 5 day dosing schedule. -
FIG. 2 shows the increased lifespan of mice treated with Compound A for the different dosing schedules also reflected inFIG. 1 . - “Tumor control” means that the perpendicular diameters of measurable lesions have not increased by 25% or more from the last measurement. See, e.g., World Health Organization (“WHO”) Handbook for Reporting Results of Cancer Treatment, Geneva (1979). The determination of tumor control or shrinkage (also referred to as “regression”) is made by known methods. For example, by evaluation of patient symptoms, physical examination, X-ray, MRI or CAT scan or other commonly accepted evaluation modalities.
- The present invention relates to a method of treating a patient suffering with cancer, in particular colon, breast, prostate or kidney cancer as well as osteo or tissue sarcoma, comprising administering to the patient Compound A in an amount of from about 800 to about 3000 mg/day, or from about 1000 to about 2500 mg/day, or from about 1250 to about 1800 mg/day, for an administration period of up to about 7 days, preferably up to about 5 days, on days 1-7, or preferably days 1-5, of a 28 day treatment cycle, followed by a rest period of from about 21 to about 23 days, preferably up to about 23 days. The course of a preferred cycle is about 28 days, though cycles anywhere between about 14 and about 28 days are contemplated. This treatment cycle is repeated for as long as the tumor remains under control and the regimen is clinically tolerated.
- Dosages of Compound A can be applied either as a body surface area (“BSA”) adapted dose (mg/m2/day) or following flat dosing (mg/day). Compound A may be administered as a single dose daily or divided into multiple daily doses.
- A patient's body measurement in square meters (“m2”) typically ranges from about 1.4 m2 to about 2.2 m2. Thus, the total amount of Compound A to be delivered in a treatment cycle (mg) using a BSA adapted dose would be calculated as follows:
-
[Dose intensity(mg/m2/week)]×[BSA(m2)]×[number of weeks in treatment cycle]. - In an embodiment, Compound A is administered daily for about 5 days, on days 1-5 of a treatment cycle, followed by a rest period of 23 days (“5+/23−”). The 5+/23− treatment schedule is expected to be superior to interim schedules or to longer schedules as currently on-going Phase I studies indicate that in solid tumors, maximal apoptosis occurs only after about 48 hours of continuous exposure and longer schedules seem to present occurrence of delayed thrombocytopenia (“TCP”). Thus, a 3-5 daily treatment schedule is expected to provide the best benefit ratio taking into consideration efficacy and toxicity
- Compound A is administered daily, either once or twice (bid) daily, preferably once daily. The compound is administered to the patient in an oral unit dosage form, most preferably in tablet form.
- Preferably, the 5 day treatment schedule is repeated every twenty-eight days, or as soon as permitted by recovery from toxicity, for so long as the tumor is under control or regressing and the patient tolerates the regimen. Preferably, these treatment cycles are repeated for a total of up to about 12 cycles.
- In an embodiment, Compound A is administered daily in an amount from about 800 to about 3000 mg/day for up to about 5 days on days 1-5 of a 28 day cycle.
- In another embodiment, Compound A is administered daily in an amount from about 1000 to about 2500 mg/day for up to about 5 days on days 1-5 of a 28 day cycle.
- In another embodiment, Compound A is administered daily in an amount from about 1250 to about 1800 mg/day for up to about 5 days on days 1-5 of a 28 day cycle.
- The present invention may be exemplified by controlled preclinical animal studies as shown in the Examples below, which illustrates the invention without limitation.
- The superiority of the 5 day regimen of the present invention on solid tumors is demonstrated by the following experiments.
- Abbreviations used herein are as follows:
-
x times po orally bid twice daily wk week qd once daily qdx5 once daily for five days qweekly or 1x/wk once a week BWL body weight loss SD standard deviation - In the examples below, weight loss was graphically represented as percent change in mean group body weight, using the formula: ((W−W0)/W0)×100, where ‘W’ represents mean body weight of the treated group at a particular day, and ‘W0’ represents mean body weight of the same treated group at initiation of treatment. Maximum weight loss was also represented using the above formula, and indicated the maximum percent body weight loss that was observed at any time during the entire experiment for a particular group. Toxicity is defined as ≧20% of mice in a given group demonstrating ≧20% body weight loss and/or death.
- Efficacy data was graphically represented as the mean tumor volume±standard error of the mean (SEM). In addition, tumor volumes of treated groups were presented as percentages of tumor volumes of the control groups (% T/C), using the formula: 100×((T−T0)/(C−C0)), where T represented mean tumor volume of a treated group on a specific day during the experiment, T0 represented mean tumor volume of the same treated group on the first day of treatment; C represented mean tumor volume of a control group on the specific day during the experiment, and C0 represented mean tumor volume of the same treated group on the first day of treatment.
- Tumor volume (in cubic millimeters) was calculated using the ellipsoid formula: (D×(d2))/2, where “D” represents the large diameter of the tumor and “d” represents the small diameter. In some cases, tumor regression and/or percent change in tumor volume was calculated using the formula: ((T−T0)/T0)×100, where ‘T’ represents mean tumor volume of the treated group at a particular day, and ‘T0’ represents mean tumor volume of the same treated group at initiation of treatment.
- Statistical analysis was determined by the rank sum test and One Way Anova and a post-hoc Bonferroni t-test (SigmaStat, version 2.0, Jandel Scientific, San Francisco, Calif., USA). Differences between groups were considered to be significant when the probability value (p) was ≦0.05.
- For survival assessment, the percent of increased life space (ILS) was calculated as: 100×[(median survival day of treated group−median survival day of control group)/median survival day of control group]. Median survival was determined utilizing Kaplan Meier survival analysis. Survival in treated groups was statistically compared with the vehicle group and survival comparisons were done between groups using the log-rank test (Graph Pad Prism, La Jolla, Calif., USA). Differences between groups were considered significant when the probability value (p) was ≦0.05.
- The antitumor activity of Compound A in the human osteosarcoma cancer xenograft model SJASA1 in immunocompromized mice using a variety of different schedules was assessed.
- Compound A was formulated as an amorphous solid dispersion micro-bulk precipitate (MBP) powder containing 30% drug substance and 70% HPMC-AS polymer was reconstituted immediately before administration as a suspension in Klucel/Tween, and remaining suspension was discarded after dosing. All dose levels are reported as the actual dosage of Compound A rather than including drug plus polymer.
- Female athymic Crl:NU-Foxn1nu mice (10/group), obtained from Charles River Laboratories (Wilmington, Del.) were utilized when they were approximately 10-12 weeks of age and weighed 23-25 g. The health of the mice was assessed daily by gross observation and analyses of blood samples taken from sentinel animals housed on shared shelf racks. All animals were allowed to acclimate and recover from any shipping-related stress for a minimum of 72 hours prior to experimental use. Autoclaved water and irradiated food (5058-ms Pico Lab mouse chow, Purina Mills, Richmond, Ind.) were provided ad libitum, and the animals were maintained on a 12 hour light and dark cycle. Cages, bedding and water bottles were autoclaved before use and changed weekly. All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals, local regulations, and protocols approved by the Roche Animal Care and Use Committee in an AAALAC accredited facility.
- SJSA cells (ATCC) were maintained in RPMI 1640+10% (v/v) heat-inactivated FBS+1% (v/v) 200 nM L-glutamine. Each mouse received 5×106 cells in a 1:1 mixture of phosphate buffered saline and Matrigel in a total volume of 0.2 ml. Cells were implanted subcutaneously in the right flank using a 1 cc syringe and a 26 gauge needle.
- The doses selected for Compound A and schedules utilized in this study are shown in Table 1 below.
-
TABLE 1 Study Design Tumor Model Treatment Groups SJSA 1. Vehicle qd po 2. Compound A 7.5 mg/kg qd po 3. Compound A 15 mg/kg qd po 4. Compound A 30 mg/kg qd po 5. Compound A 20 mg/ kg 20 days qd po, 8 days off6. Compound A 50 mg/ kg 1x/week po7. Compound A 100 mg/ kg 1x/week po 8. Compound A 200 mg/kg (given as two 100 mg/kg doses 8 hours apart (bid)), 1x/week po 9. Compound A 50 mg/kg 4 days qd po, 10 days off x 2 cycles 10. Compound A 50 mg/kg 2 days qd po, 5 days off x 4 cycles 11. Compound A 100 mg/kg 2 days qd po, 5 days off x 4 cycles 12. Compound A 80 mg/ kg 5 days qd po, 23 days off13. Compound A 100 mg/kg 2 days qd po, 12 days off x 2 cycles - Compound A was administered orally (po) using a 1 cc syringe and 18-gauge gavage needle (0.2 ml/animal). Treatment duration was 2-4 weeks. Dates of tumor implant, treatment initiation (study start date), and termination of treatment (study end date) can be found in Table 6 below. The starting tumor volume for this study was about 220 mm3. Tumor volumes and animal body weights were measured three times per week and animals were monitored for clinical signs daily.
- The results of this experiment are summarized Tables 1-3 below and
FIGS. 1 and 2 . As can be seen, the 5 day treatment schedule yielded the greatest percent increase in life span (% ILS) as well as high percent tumor growth inhibition (% TGI) with reasonable toxicity.FIG. 1 also shows good growth inhibitory activity of the 5 day on/23 day off treatment schedule. -
TABLE 2 Toxicity Summary % Change in Body Weight at end of Maximum Maximum # of animals Group Frequency Study Day 29 % Weight loss % Weight gain ≧20% BWL Mortality Vehicle QD 13.0 −1.2 13.0 0 0 Compound A 1x/wk 9.1 4.2 9.1 0 0 100 mg/kg Compound A 1x/wk 6.3 1.9 6.3 0 0 200 mg/kg (Two 100 mg/kg doses, 8 hr apart Compound A 2 on/5 off x 4, QD 7.1 −0.8 7.1 0 0 50 mg/kg Compound A 5 on/23 off, QD 8.0 0.3 8.0 0 0 80 mg/kg Compound A 20 on/8 off, QD 1.2 −3.9 1.2 0 0 20 mg/kg Compound A 2 on/12 off x 2, QD 0.9 −0.6 1.8 0 0 100 mg/kg Compound A 4 on/10 off x 2, QD 1.2 −1.1 1.2 0 0 50 mg/kg Compound A QD 5.9 −2.2 5.9 0 0 15 mg/kg Compound A 2 on/5 off x 4, QD 1.3 −2.8 1.3 0 0 100 mg/kg Compound A QD 1.3 −0.2 1.3 0 0 30 mg/kg Compound A 1 x/wk 6.6 −0.3 6.6 0 0 50 mg/kg Compound A QD 9.0 −0.3 9.0 0 0 7.5 mg/kg -
TABLE 3 Efficacy Summary (left side) Mean Tumor Mean Tumor Group Vehicle (mm3) Start Volume (mm3) or Compound A Frequency Study Day: 11 SEM SD End Study Day: 32 SD SEM Vehicle QD 215.03 ±19.00 ±60.08 4696.49 ±785.28 ±296.91 50 mg/kg 1x/week 275.41 ±22.66 ±71.65 22.66 ±1103.00 ±348.80 7.5 mg/kg QD 240.88 ±18.01 ±56.95 18.01 ±956.45 ±302.46 100 mg/kg 1 x/week 193.61 ±9.67 ±30.57 474.73 ±273.78 ±86.58 15 mg/kg QD 232.37 ±16.42 ±51.93 16.42 ±872.83 ±276.01 50 mg/kg 2 on/5 off x 4,QD 203.43 ±18.78 ±59.39 257.29 ±102.12 ±32.29 80 mg/kg 5 on/23 off, QD 197.38 ±12.80 ±40.48 128.05 ±84.89 ±26.84 20 mg/kg 20 on/8 off, QD 207.20 ±16.97 ±53.67 315.19 ±277.51 ±87.76 100 mg/kg 2 on/12 off x 2, QD 201.40 ±9.86 ±31.18 179.88 ±154.02 ±48.71 50 mg/kg 4 on/10 off x 2, QD 213.61 ±12.09 ±38.23 244.70 ±240.07 ±75.92 100 mg/kg 2 on/5 off x 4, QD 190.78 ±25.68 ±81.22 25.68 ±15.82 ±5.00 30 mg/kg QD 250.86 ±19.35 ±61.19 19.35 ±159.01 ±50.28 100 mg/kg 200 mg/kg 224.88 ±12.02 ±38.02 158.95 ±68.86 ±21.78 (Two 100 mg/kg doses, 8 hr apart) x 1x Efficacy Summary Continued (right side) % T/C End % Inhibition P value Average % Animals % Increase P Value of Study end of study end of study Regression Partial Full per d Life versus Day: 32 Day: 32 Day: 32 per Group Regression Regression Group Span Vehicle — — — — 0 0 7 — — 43 57 <0.001 — 0 0 10 23 0.0036 34 66 <0.001 — 0 0 10 23 0.0012 6 94 <0.001 — 1 0 10 77 <0.0001 21 79 <0.001 — 0 0 10 62 <0.0001 1 99 <0.001 — 3 0 10 119 <0.0001 −2 regression <0.001 35 6 2 10 127 <0.0001 2 98 <0.001 — 5 0 10 77 <0.0001 0 regression <0.001 11 7 0 10 119 <0.0001 1 99 <0.001 — 6 0 10 112 <0.0001 −2 regression <0.001 47 9 0 10 188 <0.0001 −1 regression <0.001 13 7 0 10 127 <0.0001 −1 regression <0.001 29 7 0 10 162 <0.0001 -
TABLE 4 Survival Summary 50% 50% Treatment Vehicle % p Group Days days ILS value Vehicle QD — — — — Compound A 1 x/wk 46 26 77 <0.0001 100 mg/kg Compound A Two 100 mg/kg 68 26 162 <0.0001 200 mg/kg doses, 8 hr apart 1 x/wk Compound A 2 on/5 off x 4, 57 26 119 <0.0001 50 mg/kg QD Compound A 5 on/23 off, 59 26 127 <0.0001 80 mg/kg QD Compound A 20 on/8 off, 46 26 77 <0.0001 20 mg/kg QD Compound A 2 on/12 off x 2, 57 26 119 <0.0001 100 mg/kg QD Compound A 4 on/10 off x 2, 55 26 112 <0.0001 50 mg/kg QD Compound A QD 42 26 62 <0.0001 15 mg/kg Compound A 2 on/5 off x 4, 75 26 188 <0.0001 100 mg/kg QD Compound A QD 59 26 127 <0.0001 30 mg/ kg Compound A 1 x/wk 32 26 23 0.0036 50 mg/kg Compound A QD 32 26 23 0.0012 7.5 mg/kg - Overall, the 5 days on and 23 days off (5+/23−) schedule is predicted to reduce MDM2 inhibitor-induced thrombocytopenia in humans undergoing treatment for solid tumors, while still maintaining antitumor efficacy, as compared to other regimens considered.
Claims (11)
1. A method of treating a patient suffering form cancer, comprising administering to said patient a pharmaceutical composition containing as an active ingredient Compound A in an amount from about 800 mg/day to about 3000 mg/day, daily, for up to about 7 days, followed by a rest period of up to about 21 days, said administration starting on the first day of a 28 day treatment cycle.
2. A method of treating a patient suffering form cancer, comprising administering to said patient a pharmaceutical composition containing as an active ingredient Compound A in an amount from about 800 mg/day to about 3000 mg/day, daily, for up to about 5 days, followed by a rest period of up to about 23 days, said administration starting on the first day of a 28 day treatment cycle.
3. The method of claim 2 wherein Compound A is administered in an amount from about 1000 mg/day to about 2500 mg/day.
4. The method of claim 3 wherein Compound A is administered in an amount of from about 1250 mg/day to about 1800 mg/day.
5. The method of claim 1 wherein the treatment cycle being repeated every 28 days for up to about 12 cycles.
6. The method of claim 1 wherein Compound A is administered twice daily in equal doses.
7. The method of claim 1 wherein the cancer is colorectal cancer.
8. The method of claim 1 wherein the cancer is prostate cancer.
9. The method of claim 1 wherein the cancer is lung cancer.
10. The method of claim 1 wherein the cancer is kidney cancer.
11. The method of claim 1 wherein the cancer is breast cancer.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/759,647 US20130245089A1 (en) | 2012-03-19 | 2013-02-05 | Method for administration |
US14/217,929 US20140200255A1 (en) | 2012-03-19 | 2014-03-18 | Method for administration |
US14/596,747 US20150126575A1 (en) | 2012-03-19 | 2015-01-14 | Method for administration |
US14/673,153 US20150202182A1 (en) | 2012-03-19 | 2015-03-30 | Method for administration |
US16/510,256 US20190328708A1 (en) | 2012-03-19 | 2019-07-12 | Method for administration |
US16/519,516 US11382892B2 (en) | 2012-03-19 | 2019-07-23 | Method for administration |
US16/951,153 US11738003B2 (en) | 2012-03-19 | 2020-11-18 | Method for administration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261612429P | 2012-03-19 | 2012-03-19 | |
US13/759,647 US20130245089A1 (en) | 2012-03-19 | 2013-02-05 | Method for administration |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/217,929 Continuation-In-Part US20140200255A1 (en) | 2012-03-19 | 2014-03-18 | Method for administration |
US14/596,747 Continuation US20150126575A1 (en) | 2012-03-19 | 2015-01-14 | Method for administration |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130245089A1 true US20130245089A1 (en) | 2013-09-19 |
Family
ID=47913395
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/759,647 Abandoned US20130245089A1 (en) | 2012-03-19 | 2013-02-05 | Method for administration |
US14/596,747 Abandoned US20150126575A1 (en) | 2012-03-19 | 2015-01-14 | Method for administration |
US16/510,256 Abandoned US20190328708A1 (en) | 2012-03-19 | 2019-07-12 | Method for administration |
US16/951,153 Active 2033-05-09 US11738003B2 (en) | 2012-03-19 | 2020-11-18 | Method for administration |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/596,747 Abandoned US20150126575A1 (en) | 2012-03-19 | 2015-01-14 | Method for administration |
US16/510,256 Abandoned US20190328708A1 (en) | 2012-03-19 | 2019-07-12 | Method for administration |
US16/951,153 Active 2033-05-09 US11738003B2 (en) | 2012-03-19 | 2020-11-18 | Method for administration |
Country Status (21)
Country | Link |
---|---|
US (4) | US20130245089A1 (en) |
EP (1) | EP2827858B1 (en) |
JP (2) | JP6224690B2 (en) |
KR (4) | KR20190035957A (en) |
CN (2) | CN110013478A (en) |
BR (1) | BR112014018135A8 (en) |
CA (1) | CA2859940C (en) |
CY (1) | CY1118070T1 (en) |
DK (1) | DK2827858T3 (en) |
ES (1) | ES2593066T3 (en) |
HK (1) | HK1204934A1 (en) |
HR (1) | HRP20161295T1 (en) |
HU (1) | HUE029933T2 (en) |
LT (1) | LT2827858T (en) |
MX (1) | MX356948B (en) |
PL (1) | PL2827858T3 (en) |
PT (1) | PT2827858T (en) |
RS (1) | RS55250B1 (en) |
RU (1) | RU2638795C2 (en) |
SI (1) | SI2827858T1 (en) |
WO (1) | WO2013139687A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015198266A1 (en) | 2014-06-26 | 2015-12-30 | Novartis Ag | Intermittent dosing of mdm2 inhibitor |
US20170227544A1 (en) * | 2014-10-10 | 2017-08-10 | Hoffmann-La Roche Inc. | Methods for personalizing patient cancer therapy with an mdm2 antagonist |
WO2018092020A1 (en) | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
WO2018178925A1 (en) | 2017-03-31 | 2018-10-04 | Novartis Ag | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
EP3459933A3 (en) * | 2014-04-15 | 2019-05-29 | F. Hoffmann-La Roche AG | Solid forms of a pharmaceutically active compound |
WO2019180576A1 (en) | 2018-03-20 | 2019-09-26 | Novartis Ag | Pharmaceutical combinations |
WO2020128892A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Extended low dose regimens for mdm2 inhibitors |
US11192898B2 (en) | 2016-04-06 | 2021-12-07 | The Regents Of The University Of Michigan | MDM2 protein degraders |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY192032A (en) * | 2013-01-22 | 2022-07-24 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
CN116874608A (en) | 2017-03-27 | 2023-10-13 | 诺伊尓免疫生物科技株式会社 | Chimeric antigen receptor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100152190A1 (en) * | 2008-09-18 | 2010-06-17 | David Joseph Bartkovitz | Substituted Pyrrolidine-2-Carboxamides |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101595107A (en) * | 2006-06-30 | 2009-12-02 | 先灵公司 | Can improve that P53 is active substituted piperidine and uses thereof |
WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
-
2013
- 2013-02-05 US US13/759,647 patent/US20130245089A1/en not_active Abandoned
- 2013-03-15 LT LTEP13711004.5T patent/LT2827858T/en unknown
- 2013-03-15 SI SI201330310A patent/SI2827858T1/en unknown
- 2013-03-15 ES ES13711004.5T patent/ES2593066T3/en active Active
- 2013-03-15 CN CN201910030832.0A patent/CN110013478A/en active Pending
- 2013-03-15 KR KR1020197008801A patent/KR20190035957A/en active Application Filing
- 2013-03-15 WO PCT/EP2013/055324 patent/WO2013139687A1/en active Application Filing
- 2013-03-15 KR KR1020167019798A patent/KR20160089549A/en active Application Filing
- 2013-03-15 RS RS20160860A patent/RS55250B1/en unknown
- 2013-03-15 HU HUE13711004A patent/HUE029933T2/en unknown
- 2013-03-15 PT PT137110045T patent/PT2827858T/en unknown
- 2013-03-15 RU RU2014141365A patent/RU2638795C2/en active
- 2013-03-15 CN CN201380015189.5A patent/CN104203232A/en active Pending
- 2013-03-15 MX MX2014010586A patent/MX356948B/en active IP Right Grant
- 2013-03-15 CA CA2859940A patent/CA2859940C/en active Active
- 2013-03-15 JP JP2015500851A patent/JP6224690B2/en active Active
- 2013-03-15 KR KR1020217003250A patent/KR102438597B1/en active IP Right Grant
- 2013-03-15 BR BR112014018135A patent/BR112014018135A8/en not_active Application Discontinuation
- 2013-03-15 KR KR1020147026019A patent/KR20140133583A/en active Application Filing
- 2013-03-15 EP EP13711004.5A patent/EP2827858B1/en active Active
- 2013-03-15 PL PL13711004T patent/PL2827858T3/en unknown
- 2013-03-15 DK DK13711004.5T patent/DK2827858T3/en active
-
2015
- 2015-01-14 US US14/596,747 patent/US20150126575A1/en not_active Abandoned
- 2015-06-10 HK HK15105538.1A patent/HK1204934A1/en unknown
-
2016
- 2016-10-05 CY CY20161100996T patent/CY1118070T1/en unknown
- 2016-10-06 JP JP2016197838A patent/JP2017061461A/en active Pending
- 2016-10-07 HR HRP20161295TT patent/HRP20161295T1/en unknown
-
2019
- 2019-07-12 US US16/510,256 patent/US20190328708A1/en not_active Abandoned
-
2020
- 2020-11-18 US US16/951,153 patent/US11738003B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100152190A1 (en) * | 2008-09-18 | 2010-06-17 | David Joseph Bartkovitz | Substituted Pyrrolidine-2-Carboxamides |
Non-Patent Citations (3)
Title |
---|
Kline et al. Solid Tumors in Children. Journal of Pediatric Nursing, (2003) vol. 18, 96-102. * |
Penel et al. Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC French Sarcoma Group (GSF-GETO) phase II trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol. 25, No 18S (June 20 Supplement), 2007: 10002. * |
Zalupski et al. Adjuvant Therapy of Osteosarcoma-A Phase II Trial. Cancer (2004) vol. 100, pp.818-825. * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3459933A3 (en) * | 2014-04-15 | 2019-05-29 | F. Hoffmann-La Roche AG | Solid forms of a pharmaceutically active compound |
EP3160463B1 (en) | 2014-06-26 | 2020-10-21 | Novartis AG | Intermittent dosing of mdm2 inhibitor |
US11419870B2 (en) | 2014-06-26 | 2022-08-23 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
WO2015198266A1 (en) | 2014-06-26 | 2015-12-30 | Novartis Ag | Intermittent dosing of mdm2 inhibitor |
US20170227544A1 (en) * | 2014-10-10 | 2017-08-10 | Hoffmann-La Roche Inc. | Methods for personalizing patient cancer therapy with an mdm2 antagonist |
US11192898B2 (en) | 2016-04-06 | 2021-12-07 | The Regents Of The University Of Michigan | MDM2 protein degraders |
EP3541387B1 (en) | 2016-11-15 | 2021-04-21 | Novartis AG | Dose and regimen for hdm2-p53 interaction inhibitors |
CN109982702A (en) * | 2016-11-15 | 2019-07-05 | 诺华股份有限公司 | The dosage and scheme of HDM2-p53 interaction inhibitor |
AU2017362040B2 (en) * | 2016-11-15 | 2020-04-30 | Novartis Ag | Dose and regimen for HDM2-p53 interaction inhibitors |
WO2018092020A1 (en) | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
RU2762573C2 (en) * | 2016-11-15 | 2021-12-21 | Новартис Аг | Dose and injection mode for inhibitors of interaction of hdm2 with p53 |
AU2017362040C1 (en) * | 2016-11-15 | 2020-09-10 | Novartis Ag | Dose and regimen for HDM2-p53 interaction inhibitors |
US20190298719A1 (en) * | 2016-11-15 | 2019-10-03 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
US10966978B2 (en) | 2016-11-15 | 2021-04-06 | Novartis Ag | Dose and regimen for HDM2-p53 interaction inhibitors |
WO2018178925A1 (en) | 2017-03-31 | 2018-10-04 | Novartis Ag | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
WO2019180576A1 (en) | 2018-03-20 | 2019-09-26 | Novartis Ag | Pharmaceutical combinations |
WO2020128894A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer |
WO2020128898A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Pharmaceutical combinations |
WO2020128892A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Extended low dose regimens for mdm2 inhibitors |
EP4249513A2 (en) | 2018-12-20 | 2023-09-27 | Novartis AG | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11738003B2 (en) | Method for administration | |
US20200269041A1 (en) | Treating Gastric Cancer Using TTFields Combined with XELOX, FOLFOX or the Individual Constituents Thereof | |
US9486445B2 (en) | Combination therapy for proliferative disorders | |
CN104220057B (en) | Pharmaceutical composition and method | |
JP6568052B2 (en) | Sustained release of neuregulin to treat heart failure | |
HUE027516T2 (en) | Combination therapy with an antitumor alkaloid | |
JP2014513705A (en) | Method for treating advanced solid tumors | |
Wypij et al. | Pamidronate disodium for palliative therapy of feline bone-invasive tumors | |
US11382892B2 (en) | Method for administration | |
US11285143B2 (en) | Use of mTOR inhibitor and chloroquine for treating cancer | |
CN102614180A (en) | Use of itraconazole in preparation of drug for treating multiple myeloma | |
JP2024516795A (en) | Combination containing everolimus and amsenestrant | |
von Haehling et al. | Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial | |
SCHNEIDER | File Claims by Oct. for UnitedHealth Settlement | |
Simić-Pašalić | Efficacy and safety of once-monthly ibandronate treatment in patients with low bone mineral density–ESTHER study: 24 months of follow-up | |
Anderson | CDC: One in Four Adults Uninsured Last Year | |
KüçükoĞlu | Intoxication Due to High Dose Methotrexate in a Patient with Rheumatoid Arthritis: A Case Report. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GLENN, KELLI;HIGGINS, BRIAN;NICHOLS, GWEN;AND OTHERS;REEL/FRAME:029764/0543 Effective date: 20120315 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |